Liraglutide vs Tirzepatide
How they differ
- FDA status, the same for both (FDA-approved). Liraglutide: FDA-approved as Victoza, Saxenda and generic versions.1,2,3,4 Tirzepatide: FDA-approved as Mounjaro and Zepbound.5,6,7
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Liraglutide | Tirzepatide |
|---|---|---|
| What it is | A GLP-1 receptor agonist. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.1 | A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.5 |
| FDA status | FDA-approved FDA-approved as Victoza, Saxenda and generic versions1,2,3,4 FDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.1,2,3,4 | FDA-approved FDA-approved as Mounjaro and Zepbound5,6,7 FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.5,6,7 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.8 | Not among the six peptides the policy lists.8 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 82 ClinicalTrials.gov records and 58 PubMed records collected | 108 ClinicalTrials.gov records and 75 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 6Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 10Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 11Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 12FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 13FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 14FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026